Comparisons, without a winner's podium.

Evidence at a glance

Side effects · Doses used in studies · What citicoline is

A closer reading

Why this hub exists

Search for citicoline online and you will find list after list ranking it against other choline sources, "nootropic stacks," and brain-health ingredients. Most of those rankings have no trial behind them. They compare marketing copy, not evidence. This hub takes a different approach. It treats a comparison as a question about names, doses, and study designs, not as a contest with a trophy at the end.

Citicoline (CDP-choline) is a defined compound with a published trial record. That record includes large, well-run studies with negative results, alongside smaller studies with positive signals. When people ask "is citicoline better than X," the honest answer usually has two parts: what citicoline itself has been shown to do or not do, and whether the other compound has been tested at all for the same outcome. In many cases the second half of that answer is "no, it has not." A comparison cannot declare a winner when one side of the scale is empty.

What a comparison can and cannot tell you

A fair comparison of two supplements would need head-to-head trials: the same participants, the same outcomes, the same follow-up, with each compound measured against the other. For citicoline, essentially none of those trials exist against alpha-GPC, choline bitartrate, uridine, phosphatidylserine, or piracetam. What exists instead are separate bodies of evidence of very different size and quality.

This matters more than it might seem. Citicoline has been tested in trials with thousands of participants, including studies that failed to show benefit. Many of the compounds it is compared against have never faced a test that large. A compound with a thin evidence base can look appealing next to one with a deep, mixed record, not because it works better, but because its flaws have never been exposed by a rigorous negative trial. Absence of evidence is not evidence of superiority.

The citicoline evidence baseline, kept honest

Any comparison has to start with what citicoline itself has and has not shown. The largest single test was the ICTUS trial, published in The Lancet in 2012, which enrolled about 2,300 people with acute stroke. It found no improvement in 90-day recovery versus placebo. Earlier meta-analyses had suggested benefit in stroke; the largest trial did not confirm that. A companion trial, COBRIT, published in JAMA in 2012, found citicoline did not improve functional or cognitive outcomes after traumatic brain injury versus placebo.

On the other side of the ledger, the signals are more modest. A Cochrane review by Fioravanti and Yanagi on chronic cerebrovascular cognitive decline found modest short-term benefit on memory and behaviour, but the trials were short and low in quality. The IDEALE study, an observational comparison in mild vascular cognitive impairment, associated citicoline with stable scores versus decline in an untreated group, an association, not proof. Small glaucoma trials from the Parisi and Rossetti groups showed changes on electrophysiological measures; an effect on actual vision loss has not been established. In healthy women, the industry-funded McGlade 2012 study at 250 and 500 mg found better attention-test scores, and a similar small, industry-funded study in adolescent males found attention and psychomotor speed gains. For ADHD, there are no adequate trials, and there is no good evidence citicoline treats ADHD.

Because stroke comes up wherever citicoline is discussed: sudden facial droop, arm weakness, or speech difficulty can be a stroke. Call 911 immediately. No supplement is a substitute for emergency care.

How to read a "versus" claim

When a website declares citicoline superior or inferior to another compound, a few questions cut through it quickly. Which compound was actually given in the study being cited, and at what dose? Was the study a randomized trial or an observation? Was it in people with the condition you care about, or in healthy volunteers taking a brief attention test? Who funded it? And, the question most rankings skip, has the other compound ever been tested on the same outcome at all?

Dose deserves special attention. Choline compounds differ in how much usable choline they deliver per milligram, so comparing bottle labels milligram-for-milligram is misleading even before you ask whether either dose was studied. The doses that appear in citicoline trials, generally 250 to 2,000 mg per day, where it was well tolerated with mild side effects such as stomach upset, headache, and insomnia, are catalogued on the doses used in studies page, with tolerability detail on the side effects page.

The comparisons, one by one

Alpha-GPC is the comparison most often searched, and it has its own page: citicoline versus alpha-GPC. That page explains what each name refers to chemically and why the evidence does not support crowning either one.

Choline bitartrate is a different choline salt, not a synonym. Citicoline is CDP-choline, the same compound sometimes sold under the Cognizin brand, which is a brand of that molecule, not a different molecule (see CDP-choline and citicoline and what Cognizin is). Choline bitartrate shares the word "choline" and little else in terms of trial record.

Uridine and phosphatidylserine are often stacked with citicoline because of a plausible-sounding story about membrane phospholipid synthesis. The mechanism story is real at the preclinical level, evidence suggests citicoline supports membrane phospholipid synthesis, but neuroprotection from that pathway has only been shown in preclinical work. A plausible mechanism shared by two compounds is not a clinical comparison of either.

Piracetam belongs to a different category entirely, with its own distinct regulatory status and evidence base. Grouping it with citicoline because both appear on "nootropic" shelves is a retail decision, not a scientific one.

None of these get their own page yet, and that is deliberate. A page will only be written when it can meet the same standard as the alpha-GPC page. Until then, this hub will not pad the gaps with unsourced rankings.

Why the negative trials set the standard here

It would be easy to build a comparison site that quotes only the encouraging studies. That is exactly how most supplement rankings are built. The problem is that citicoline's two largest trials, ICTUS in stroke and COBRIT in brain injury, were negative, and they were better designed than most of the positive ones. Any honest account of citicoline has to hold both facts at once, and any comparison built on only the positive half is not a comparison of the evidence. It is a comparison of brochures.

The full condition-by-condition record, with both the negative and positive trials, lives on the evidence hub, including dedicated pages on memory, ADHD, and glaucoma. Claims on this hub cannot be stronger than what that register supports, and this hub never claims citicoline treats, cures, reverses, or prevents any condition.

What to take to your clinician

If you are weighing citicoline against another compound, the most useful questions are simple. Which compound was studied for the outcome you care about? At what dose, and for how long? And does it interact with anything you already take? One interaction worth naming here: citicoline may enhance the effects of levodopa, so people with Parkinson's disease should involve their neurologist before adding it. Pregnancy and breastfeeding safety data are lacking, which is another conversation to have before, not after.

For a structured list, see questions to ask your doctor. If you and your clinician decide a choline supplement makes sense, the editorial buying guide explains how to read a label, without this site selling you anything, because evidence pages here carry no affiliate links and no product recommendations.

The short version

Citicoline is a well-studied compound with a mixed record: negative results in its largest stroke and brain-injury trials, modest and lower-quality signals in cognitive decline and attention. Most compounds it is compared against have never faced trials of that size. Until head-to-head evidence exists, this hub's job is to keep the names straight, keep the negative trials as visible as the positive ones, and refuse to hand out medals the data have not earned.